重组人血管内皮抑制素腔内注射治疗恶性腹腔积液的研究进展

Progression of recombinant human endostatin (endostar) intraperitoneal injection for the treatment of malignant ascites

恶性腹腔积液(MA)是指由于恶性肿瘤局部侵犯腹膜或转移引起液体在腹膜腔内的病理性聚积。MA是晚期恶性肿瘤常见的并发症之一,患者预后往往较差,临床上尚缺乏公认的标准治疗药物和方案。MA的形成与原发肿瘤类型和位置存在相关性。当前MA治疗主要为全身化疗、腹腔内灌注化疗、腹腔热灌注化疗和腹腔内免疫治疗等。近年来,随着研究的深入,采用腹腔内注射重组人血管内皮抑制素(恩度)抗血管新生治疗的报告比较多,业已成为治疗MA的有效策略和方法。为了更好地指导临床上合理治疗MA,本文根据恩度腹腔内注射治疗MA的相关临床研究和临床观察经验,结合国内、外相关文献,对恩度治疗MA的研究进展进行综述。

Malignant ascites(MA)is the pathological accumulation of malignant peritoneal fluid in the peritoneal cavity caused by tumor invasion or metastasis.MA is one of the many complications of patients with advanced tumor.The prognosis of those patients is poor while there are still no standard drugs or treatment regimens.The formation mechanism of MA varies with the pathology and location of primary tumor.Currently,MA can be treated by systemic chemotherapy,intraperitoneal chemotherapy,hyperthermic intraperitoneal chemotherapy,intraperitoneal immunotherapy and other treatment methods.In recent years,intraperitoneal anti-angiogenesis therapy with recombinant human endostatin injection(endostar)has been reported wildly and shown very promising efficacy in treating MA.Based on the experience of clinical observation and the related publications of endostar,the advancement of endostar in the treatment of MA was systemically reviewedin this article.